Application
Western blot analysis of extracts from 293 cells untreated or treated with EGF using HDAC4/HDAC5/HDAC9 (phospho-Ser246/259/220) Antibody .Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HDAC4/HDAC5/HDAC9 (Phospho-Ser246/259/220) Antibody (left) or the same antibody preincubated with blocking peptide (right).Application
Western blot analysis of extracts from 293 cells untreated or treated with EGF using HDAC4/HDAC5/HDAC9 (phospho-Ser246/259/220) Antibody| Product Name | HDAC4/HDAC5/HDAC9 (phospho Ser246/259/220) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to HDAC4/HDAC5/HDAC9 (Phospho Ser246/259/220)Histone Deacetylases (HDACs) are a group of enzymes closely related to sirtuins. They catalyze the removal of acetyl groups from lysine residues in histones and non-histone proteins, resulting in transcriptional repression. In general,they do not act autonomously but as components of large multiprotein complexes, such as pRb-E2F and mSin3A, that mediate important transcription regulatory pathways. There are three classes of HDACs; classes 1, 2 and 4, which are closely related Zn2+-dependent enzymes. HDACs are ubiquitously expressed and they can exist in the nucleus or cytosol. Their subcellular localization is effected by protein-protein interactions (for example HDAC-14.3.3 complexes are retained in the cytosol) and by the class to which they belong (class 1 HDACs are predominantly nuclear whilst class 2 HDACs shuttle between the nucleus and cytosol). HDACs have a role in cell growth arrest, differentiation and death and this has led to substantial interest in HDAC inhibitors as possible antineoplastic agents. |
| Immunogen | Peptide sequence around phosphorylation site of serine 246/259/220 (T-A-S(p)-EP) derived from Human HDAC4/HDAC5/HDAC9. |
| Modification | p-Ser246/259/220 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | IHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user. | |
| Species Reactivity | Human |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | AHO3, BDMR, HA6116, HD4, HDAC-A, HDACA, KIAA0288, HDAC4, histone deacetylase 4, histone deacetylase A, FLJ90614, HD5, NY-CO-9, HDAC5, histone deacetylase 5, antigen NY-CO-9, DKFZp779K1053, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, KIAA074 |
|---|---|
| Target | HDAC4/HDAC5/HDAC9 (Phospho Ser246/259/220) |
| Molecular Weight(MW) | 140, 124 (note) |
Application
Western blot analysis of extracts from 293 cells untreated or treated with EGF using HDAC4/HDAC5/HDAC9 (phospho-Ser246/259/220) Antibody .
Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HDAC4/HDAC5/HDAC9 (Phospho-Ser246/259/220) Antibody (left) or the same antibody preincubated with blocking peptide (right).
Application
Western blot analysis of extracts from 293 cells untreated or treated with EGF using HDAC4/HDAC5/HDAC9 (phospho-Ser246/259/220) Antibody| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user. |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
